Targeting the adaptor protein Gab1 overcomes MET/Src-driven alectinib resistance in ALK-rearranged NSCLC
Cellular Signalling · 2026-11 · 147 · 112750
DOI: 10.1016/j.cellsig.2026.112750 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2026-11. Verfasst von Hengyi Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, The Seventh People's Hospital of Chongqing, Chongqing, China. Electronic address: hilliry@126.com. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drug Resistance, Neoplasm, Carbazoles. Die Arbeit nennt 45 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: In non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) rearrangement, bypass signaling activation commonly leads to resistance against alectinib. Identifying key molecular targets that integrate signals from resistance-driving kinases is crucial for overcoming this resistance. However, these targets have not yet been identified. METHODS: We generated alectinib-resistant (AR) subclones from H3122 and H2228 cells. Subsequently, we analyzed bypass signaling pathways using western blotting, evaluated drug sensitivity with Cell Counting Kit-8 (CCK-8) assays. To assess the function of Grb2-associated binder 1 (Gab1), we employed siRNA-mediated knockdown and lentiviral shRNA both in vitro and in xenograft models. Additionally, we determined the stability of Gab1 through cycloheximide chase assays. RESULTS: AR cells demonstrated concurrent activation of the mesenchymal epithelial transition receptor tyrosine kinase (MET) and Rous sarcoma oncogene cellular homolog non-receptor tyrosine kinase (Src), accompanied by upregulation of Gab1. The combined inhibition of MET and Src, as opposed to single-agent blockade, effectively suppressed Gab1/protein kinase B (AKT) signaling and restored sensitivity to alectinib. Gab1 knockdown mirrored the effects of dual kinase inhibition, by disrupting MET/Src/AKT signaling and resensitizing cells to alectinib. Mechanistically, the elevation of Gab1 resulted from post - translational stabilization, with a significantly extended half - life in resistant cells. In vivo, silencing Gab1 inhibited the growth of H3122-AR2 xenografts without causing systemic toxicity, which correlated with decreased phosphorylation of MET, Src and AKT in tumor tissues. CONCLUSION: In ALK-positive NSCLC with acquired resistance to alectinib, Gab1 emerged as a crucial downstream signaling convergence target of MET and Src co-activation. Targeting this adaptor protein presented a promising therapeutic strategy to overcome bypass-mediated resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, The Seventh People's Hospital of Chongqing, Chongqing, China. Electronic address: hilliry@126.com.
- Department of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.
- Department of Pulmonary and Critical Care Medicine, The Seventh People's Hospital of Chongqing, Chongqing, China.
- Department of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China. Electronic address: heyong@tmmu.edu.cn.
Zitieren
APA
Chen, H., Lin, C., Hu, C., Li, W., & He, Y. (2026). Targeting the adaptor protein Gab1 overcomes MET/Src-driven alectinib resistance in ALK-rearranged NSCLC. Cellular Signalling, 147, 112750. https://doi.org/10.1016/j.cellsig.2026.112750
Vancouver
Chen H, Lin C, Hu C, Li W, He Y. Targeting the adaptor protein Gab1 overcomes MET/Src-driven alectinib resistance in ALK-rearranged NSCLC. Cellular Signalling. 2026;147:112750. doi:10.1016/j.cellsig.2026.112750
BibTeX
@article{Chen2026,
author = {Chen, Hengyi and Lin, Caiyu and Hu, Chen and Li, Wen and He, Yong},
title = {Targeting the adaptor protein Gab1 overcomes MET/Src-driven alectinib resistance in ALK-rearranged NSCLC},
journal = {Cellular Signalling},
year = {2026},
volume = {147},
pages = {112750},
doi = {10.1016/j.cellsig.2026.112750}
}
EUVIMED